THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Joan Walker to Neoplasm Staging

Back to Details
This is a "connection" page, showing publications Joan Walker has written about Neoplasm Staging.
Joan Walker
Connection Strength
2.169
Neoplasm Staging
  1. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. J Clin Oncol. 2009 Nov 10; 27(32):5331-6.
    View in: PubMed
    Score: 0.305
  2. Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2019 06 01; 37(16):1380-1390.
    View in: PubMed
    Score: 0.148
  3. Pathologic and Treatment Outcomes Among a Geriatric Population of Endometrial Cancer Patients: An NRG Oncology/Gynecologic Oncology Group Ancillary Data Analysis of LAP2. Int J Gynecol Cancer. 2017 05; 27(4):730-737.
    View in: PubMed
    Score: 0.129
  4. Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis. Gynecol Oncol. 2016 Dec; 143(3):460-465.
    View in: PubMed
    Score: 0.124
  5. The impact of obesity on surgical staging, complications, and survival with uterine cancer: a Gynecologic Oncology Group LAP2 ancillary data study. Gynecol Oncol. 2014 Apr; 133(1):23-7.
    View in: PubMed
    Score: 0.104
  6. Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol. 2013 Jul; 130(1):12-8.
    View in: PubMed
    Score: 0.097
  7. Comparison of clinical versus surgical staging systems in vulvar cancer. Obstet Gynecol. 1992 Dec; 80(6):927-30.
    View in: PubMed
    Score: 0.095
  8. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. J Clin Oncol. 2012 Mar 01; 30(7):695-700.
    View in: PubMed
    Score: 0.090
  9. A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Apr; 125(1):54-8.
    View in: PubMed
    Score: 0.089
  10. Quality of life of patients with endometrial cancer undergoing laparoscopic international federation of gynecology and obstetrics staging compared with laparotomy: a Gynecologic Oncology Group study. J Clin Oncol. 2009 Nov 10; 27(32):5337-42.
    View in: PubMed
    Score: 0.076
  11. A phase I/II study of extended field radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in patients with cervical carcinoma metastatic to the para-aortic lymph nodes: a Gynecologic Oncology Group study. Gynecol Oncol. 2009 Jan; 112(1):78-84.
    View in: PubMed
    Score: 0.072
  12. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 2006 Jan; 100(1):27-32.
    View in: PubMed
    Score: 0.059
  13. Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2022 02; 164(2):398-405.
    View in: PubMed
    Score: 0.044
  14. Receipt of adjuvant endometrial cancer treatment according to race: an NRG Oncology/Gynecologic Oncology Group 210 Study. Am J Obstet Gynecol. 2018 11; 219(5):459.e1-459.e11.
    View in: PubMed
    Score: 0.035
  15. CT Perfusion as an Early Biomarker of Treatment Efficacy in Advanced Ovarian Cancer: An ACRIN and GOG Study. Clin Cancer Res. 2017 Jul 15; 23(14):3684-3691.
    View in: PubMed
    Score: 0.032
  16. Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study. Gynecol Oncol. 2016 Dec; 143(3):484-489.
    View in: PubMed
    Score: 0.031
  17. Expression Patterns of the Wnt Pathway Inhibitors Dickkopf3 and Secreted Frizzled-Related Proteins 1 and 4 in Endometrial Endometrioid Adenocarcinoma: An NRG Oncology/Gynecologic Oncology Group Study. Int J Gynecol Cancer. 2016 Jan; 26(1):125-32.
    View in: PubMed
    Score: 0.029
  18. Update on Intraperitoneal Chemotherapy for the Treatment of Epithelial Ovarian Cancer. Am Soc Clin Oncol Educ Book. 2016; 35:143-51.
    View in: PubMed
    Score: 0.029
  19. Relationships of Tubal Ligation to Endometrial Carcinoma Stage and Mortality in the NRG Oncology/ Gynecologic Oncology Group 210 Trial. J Natl Cancer Inst. 2015 Sep; 107(9).
    View in: PubMed
    Score: 0.028
  20. A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015 Jul; 138(1):36-40.
    View in: PubMed
    Score: 0.028
  21. Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study. Int J Gynecol Cancer. 2014 Nov; 24(9):1583-9.
    View in: PubMed
    Score: 0.027
  22. Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol. 2014 Apr 20; 32(12):1210-7.
    View in: PubMed
    Score: 0.026
  23. Phase II trial of vaginal cuff brachytherapy followed by chemotherapy in early stage endometrial cancer patients with high-intermediate risk factors. Gynecol Oncol. 2014 Jan; 132(1):50-4.
    View in: PubMed
    Score: 0.025
  24. Evaluation of a multiplex panel of immune-related markers in cervical secretions: a methodologic study. Int J Cancer. 2014 Jan 15; 134(2):411-25.
    View in: PubMed
    Score: 0.025
  25. Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial. Gynecol Oncol. 2013 May; 129(2):277-84.
    View in: PubMed
    Score: 0.024
  26. Nodal metastasis risk in endometrioid endometrial cancer. Obstet Gynecol. 2012 Feb; 119(2 Pt 1):286-92.
    View in: PubMed
    Score: 0.022
  27. Serum profiling to distinguish early- and late-stage ovarian cancer patients from disease-free individuals. Cancer Invest. 2012 Feb; 30(2):189-97.
    View in: PubMed
    Score: 0.022
  28. Do uterine risk factors or lymph node metastasis more significantly affect recurrence in patients with endometrioid adenocarcinoma? Gynecol Oncol. 2012 Apr; 125(1):94-8.
    View in: PubMed
    Score: 0.022
  29. Carbonic anhydrase IX and human papillomavirus as diagnostic biomarkers of cervical dysplasia/neoplasia in women with a cytologic diagnosis of atypical glandular cells: a Gynecologic Oncology Group study in United States. Int J Cancer. 2009 Nov 15; 125(10):2434-40.
    View in: PubMed
    Score: 0.019
  30. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis. Gynecol Oncol. 2009 Feb; 112(2):337-41.
    View in: PubMed
    Score: 0.018
  31. Phase I trial of the treatment of high-risk endometrial cancer with concurrent weekly paclitaxel and cisplatin and whole abdominal radiation therapy: a Gynecologic Oncology Group study. Gynecol Oncol. 2009 Jan; 112(1):134-41.
    View in: PubMed
    Score: 0.018
  32. Ovarian cancer in the octogenarian: does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply? Gynecol Oncol. 2008 Aug; 110(2):133-9.
    View in: PubMed
    Score: 0.017
  33. Validation of FACT/GOG-AD subscale for ovarian cancer-related abdominal discomfort: a Gynecologic Oncology Group study. Gynecol Oncol. 2008 Jul; 110(1):60-4.
    View in: PubMed
    Score: 0.017
  34. Extraperitoneal para-aortic lymph node evaluation for cervical cancer via pfannenstiel incision: technique and peri-operative outcomes. Gynecol Oncol. 2008 Mar; 108(3):466-71.
    View in: PubMed
    Score: 0.017
  35. Comparison of outcome measures in patients with advanced squamous cell carcinoma of the vulva treated with surgery or primary chemoradiation. Gynecol Oncol. 2008 Mar; 108(3):584-90.
    View in: PubMed
    Score: 0.017
  36. Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial. Am J Obstet Gynecol. 2007 Nov; 197(5):503.e1-6.
    View in: PubMed
    Score: 0.017
  37. Pathologic findings and outcomes for octogenarians presenting with uterine malignancy. Gynecol Oncol. 2007 Sep; 106(3):572-8.
    View in: PubMed
    Score: 0.016
  38. Lymphadenectomy in endometrioid uterine cancer staging: how many lymph nodes are enough? A study of 11,443 patients. Cancer. 2007 Jun 15; 109(12):2454-60.
    View in: PubMed
    Score: 0.016
  39. Gynecologic Oncology Group risk groups for vulvar carcinoma: improvement in survival in the modern era. Gynecol Oncol. 2007 Sep; 106(3):521-5.
    View in: PubMed
    Score: 0.016
  40. Radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in cervical carcinoma limited to the pelvis: a phase I/II study of the Gynecologic Oncology Group. Gynecol Oncol. 2006 Dec; 103(3):1038-42.
    View in: PubMed
    Score: 0.015
  41. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006 Jan 05; 354(1):34-43.
    View in: PubMed
    Score: 0.015
  42. A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference? Gynecol Oncol. 2004 Oct; 95(1):70-6.
    View in: PubMed
    Score: 0.013
  43. Surgical-pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply? Gynecol Oncol. 2004 Aug; 94(2):249-55.
    View in: PubMed
    Score: 0.013
  44. Endometrial cancer metastatic to infrarenal aortic lymph nodes unrecognized during laparoscopic inframesenteric aortic lymph node dissection. Gynecol Oncol. 2004 Apr; 93(1):260-2.
    View in: PubMed
    Score: 0.013
  45. Ligation of an anatomic variant of renal vasculature during laparoscopic periaortic lymph node dissection: a cause of postoperative renal infarction. Gynecol Oncol. 2003 Nov; 91(2):416-20.
    View in: PubMed
    Score: 0.013
  46. Method and timing of tumor volume measurement for outcome prediction in cervical cancer using magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2002 Jan 01; 52(1):14-22.
    View in: PubMed
    Score: 0.011
  47. Surgical management of early-stage endometrial cancer in the elderly: is laparoscopy feasible? Gynecol Oncol. 2001 Dec; 83(3):563-8.
    View in: PubMed
    Score: 0.011
  48. Laparoscopic pelvic and paraaortic lymph node dissection: analysis of the first 100 cases. Gynecol Oncol. 2001 Sep; 82(3):498-503.
    View in: PubMed
    Score: 0.011
  49. Analysis of FIGO Stage IIIc endometrial cancer patients. Gynecol Oncol. 2001 May; 81(2):273-8.
    View in: PubMed
    Score: 0.011
  50. Cost analysis of laparoscopy versus laparotomy for early endometrial cancer. Gynecol Oncol. 1999 Dec; 75(3):460-3.
    View in: PubMed
    Score: 0.010
  51. Incidence and location of para-aortic lymph node metastases in gynecologic malignancies. J Am Coll Surg. 1995 Jul; 181(1):72-4.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES